Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4870659
Max Phase: Preclinical
Molecular Formula: C31H34ClN7O2
Molecular Weight: 572.11
Molecule Type: Unknown
Associated Items:
ID: ALA4870659
Max Phase: Preclinical
Molecular Formula: C31H34ClN7O2
Molecular Weight: 572.11
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CCCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1
Standard InChI: InChI=1S/C31H34ClN7O2/c1-38(2)16-7-11-28(40)35-22-14-12-21(13-15-22)30(41)39-17-6-5-8-23(20-39)36-31-34-19-26(32)29(37-31)25-18-33-27-10-4-3-9-24(25)27/h3-4,7,9-15,18-19,23,33H,5-6,8,16-17,20H2,1-2H3,(H,35,40)(H,34,36,37)/b11-7+/t23-/m1/s1
Standard InChI Key: NBELKEMVBFHPAA-GULCCPCXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 572.11 | Molecular Weight (Monoisotopic): 571.2463 | AlogP: 5.44 | #Rotatable Bonds: 8 |
Polar Surface Area: 106.25 | Molecular Species: BASE | HBA: 6 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.75 | CX Basic pKa: 8.81 | CX LogP: 4.76 | CX LogD: 3.34 |
Aromatic Rings: 4 | Heavy Atoms: 41 | QED Weighted: 0.24 | Np Likeness Score: -1.21 |
1. Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, Ficarro SB, Seong BKA, Greifenberg AK, Dust S, Kwiatkowski NP, Marto JA, Stegmaier K, Zhang T, Geyer M, Gray NS.. (2021) Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma., 221 [PMID:33945934] [10.1016/j.ejmech.2021.113481] |
Source(1):